Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Cannabinoids Market

Cannabinoids Market Analysis

Report ID: GMI5320
Published Date: Sep 2022
Report Format: PDF

Download Free Sample

Cannabinoids Market Analysis

The cannabinoids market is segmented by type into cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), and cannabidiolic Acid (CBDA). The CBD segment is further sub-segmented into product and application; including the product categories CBD oil and CBD isolate and the application sub-segments of cosmetics, food and drinks, and pharmaceuticals. The CBD oil product segment is further divided into CBD broad spectrum oil and CBD full spectrum oil.

The market share is anticipated to rise in the ensuing years owing to the increasing number of people using CBD oil to treat a variety of illnesses, including anxiety, nausea, pain, inflammation, and sleep disorders. Depending on the indication, CBD oil can be simply applied or eaten. Some studies even state that CBD oil may be useful in alleviating cancer-related symptoms and some side effects pertaining to cancer treatment, such as chronic pain and nausea. Cannabidiol (CBD) segment was valued at over USD 9 billion in 2021 and is anticipated to grow significantly during the forecast period.

Learn more about the key segments shaping this market

Download Free Sample

Europe cannabinoids market is anticipated to cross USD 17 billion by 2030. Growing health consciousness among Europeans and increasing awareness of the health benefits linked with the use of cannabinoid products is leading to an increase in the number of market players in the region. Additionally, the number of government approvals for such products is also depicting an upsurge across the European economies, which is predicted to boost the market forecasts.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

In 2021, the global market for cannabinoids registered a valuation of over USD 11 billion and will expand at a CAGR of more than 20% during the forecast period of 2022-2030.

The cannabidiol (CBD) product segment was valued at over USD 9 billion in 2021 and is expected to show a considerable growth rate over the forecast period.

Europe cannabinoids market is anticipated to be worth over USD 17 billion by 2030, driven by the growing health consciousness and increasing presence of market players in the region.

The competitive landscape of the market includes companies such as Bedrocan, NuLeaf Naturals, LLC, Green Roads, Global Cannabinoids, Maricann Inc., Mile High Labs International Inc., Rhizo Sciences, Spark-CBD, and Folium Biosciences.